EUVIMEDEUVIMED entdecken
Open Access

Novel extragenic genomic safe harbors for precise therapeutic T cell engineering

Ashlesha Odak iD, Han Yuan iD, Judith Feucht, Vito Adrian Cantu iD, Jorge Mansilla-Soto iD, Friederike Kogel iD, Justin Eyquem iD, John Everett, Frederic D Bushman iD, Christina S Leslie iD, Michel Sadelain iD

Blood · 2023

DOI: 10.1182/blood.2022018924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Ashlesha Odak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: T-Lymphocytes, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell therapies that rely on engineered immune cells can be enhanced by achieving uniform and controlled transgene expression in order to maximize T cell function and achieve predictable patient responses. Although effective, current genetic engineering strategies that utilize g-retroviral, lentiviral and transposon-based vectors to integrate transgenes, unavoidably produce variegated transgene expression in addition to posing a risk of insertional mutagenesis. In the setting of chimeric antigen receptor (CAR) therapy, inconsistent and random CAR expression may result in tonic signaling, T cell exhaustion and variable T cell persistence. We report and validate herein an algorithm for the identification of extragenic genomic safe harbors (GSH) that can be efficiently targeted for DNA integration and support sustained and predictable CAR expression in human peripheral blood T cells. The algorithm is based on 7 criteria established to minimize genotoxicity by directing transgene integration away from functionally important genomic elements, maximize efficient CRISPR/Cas9-mediated targeting, and avert transgene silencing over time. T cells engineered to express a CD19 CAR at GSH6, which meets all 7 criteria, are curative at low cell dose in a mouse model of acute lymphoblastic leukemia, matching the potency of CAR T cells engineered at the TRAC locus, and effectively resist tumor rechallenge 100 days after their infusion. The identification of functional extragenic GSHs thus expands the human genome available for therapeutic precision engineering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesReceptors, Antigen, T-CellAnimalsMiceHumansGenetic VectorsImmunotherapy, AdoptiveCell EngineeringGenomicsAntigens, CD19

Substanzen

Receptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY.
  • Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Ashlesha Odak, Han Yuan, Vito Adrian Cantu, Jorge Mansilla-Soto, Friederike Kogel, Justin Eyquem, Frederic D Bushman, Christina S Leslie, Michel Sadelain

Förderung

  • NCI NIH HHS

Zitieren

APA

Odak, A., Yuan, H., Feucht, J., Cantu, V. A., Mansilla-Soto, J., Kogel, F., Eyquem, J., Everett, J., Bushman, F. D., Leslie, C. S., & Sadelain, M. (2023). Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood. https://doi.org/10.1182/blood.2022018924

Vancouver

Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, et al. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood. 2023. doi:10.1182/blood.2022018924

BibTeX
@article{Odak2023,
  author = {Odak, Ashlesha and Yuan, Han and Feucht, Judith and Cantu, Vito Adrian and Mansilla-Soto, Jorge and Kogel, Friederike and Eyquem, Justin and Everett, John and Bushman, Frederic D and Leslie, Christina S and Sadelain, Michel},
  title = {Novel extragenic genomic safe harbors for precise therapeutic T cell engineering},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018924}
}
Kostenlos starten →